All Stories

  1. Reverting the molecular fingerprint of tumor dormancy as a therapeutic strategy for glioblastoma

    Article • The FASEB Journal, June 2018, Federation of American Societies For Experimental Biology (FASEB)

    Professor Philip Lazarovici, Gadi Cohen

  2. Disintegrin-Based, Synthetic Cyclic KTS Peptides as Novel Dual Antagonists of α1β1/α2β1 Integrins with Antiangiogenic Activity

    Article • October 2016, Bentham Science Publishers

    Professor Philip Lazarovici, Dr Tatjana Momic, Johannes Eble, Professor Hanoch Senderowitz

  3. Vipegitide: a folded peptidomimetic partial antagonist of α2β1 integrin with antiplatelet aggregation activity

    Article • Drug Design Development and Therapy, January 2015, Taylor & Francis

    Professor Philip Lazarovici, Professor Hanoch Senderowitz, Dr Tatjana Momic, David Varon, Johannes Eble

  4. Nerve growth factor-induced myoprotection in C2C12 muscle cells is mediated by α9β1 integrin via release of PGE2

    Article • Journal of Basic and Clinical Physiology and Pharmacology, January 2015, De Gruyter

    Professor Philip Lazarovici